help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Skowronski, R. J.
Right arrow Articles by Feldman, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Skowronski, R. J.
Right arrow Articles by Feldman, D.

Endocrinology, Vol 136, 20-26, Copyright © 1995 by Endocrine Society

ARTICLES

Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3

RJ Skowronski, DM Peehl and D Feldman
Department of Medicine, Stanford University School of Medicine, California 94305.

Data from epidemiological studies has suggested that vitamin D deficiency may promote prostate cancer, although the mechanism is not understood. We have previously demonstrated the presence of vitamin D receptors (VDR) in three human prostate carcinoma cell lines (LNCaP, PC- 3, and DU-145) as well as in primary cultures of stromal and epithelial cells derived from normal and malignant prostate tissues. We have also shown that 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] can elicit an antiproliferative action in these cells. In the present study we compared the biological actions of 1,25-(OH)2D3 to those of a series of natural vitamin D3 metabolites and several synthetic analogs of vitamin D3 known to exhibit less hypercalcemic activity in vivo. In ligand binding competition experiments, we demonstrated the following order of potency in displacing [3H]1,25-(OH)2D3 from VDR: EB-1089 > 1,25-(OH)2D3 > MC-903 > 1,24,25-(OH)3D3 > 22-oxacalcitriol (OCT) > 1 alpha,25- dihydroxy-16-enecholecalciferol (Ro24-2637) > 25-hydroxyvitamin D3, with EB-1089 being approximately 2-fold more potent than the native hormone. No competitive activity was found for 25-hydroxy-16,23-diene- cholecalciferol. When compared for ability to inhibit proliferation of LNCaP cells, MC-903, EB-1089, OCT, and Ro24-2637 exhibited 4-, 3-, and 2-fold greater inhibitory activity than 1,25-(OH)2D3. Interestingly, although OCT and Ro24-2637 exhibit, respectively, 10 and 14 times lower affinity for VDR than 1,25-(OH)2D3, both compounds inhibited the proliferation of LNCaP cells with a potency greater than that of the native hormone. The relative potency of vitamin D3 metabolites and analogs to inhibit cell proliferation correlated well with the ability of these compounds to stimulate prostate-specific antigen secretion by LNCaP cells as well as with their potency to induce the 25- hydroxyvitamin D3-24-hydroxylase messenger RNA transcript in PC-3 cells. In conclusion, these results demonstrate that synthetic analogs of vitamin D3, known to exhibit reduced calcemic activity, can elicit antiproliferative effects and other biological actions in LNCaP and PC- 3 cell lines. It is noteworthy that although binding to VDR is critical for 1,25-(OH)2D3 action, the analog data indicate that additional factors significantly contribute to the magnitude of the biological response. Finally, the strong antiproliferative effects of several synthetic analogs known to exhibit less calcemic activity than 1,25- (OH)2D3 suggest that these compounds potentially may be useful as an additional therapeutic option for the treatment of prostate cancer.


This article has been cited by other articles:


Home page
 EndocrinologyHome page
L. A. Zella, N. K. Shevde, B. W. Hollis, N. E. Cooke, and J. W. Pike
Vitamin D-Binding Protein Influences Total Circulating Levels of 1,25-Dihydroxyvitamin D3 but Does Not Directly Modulate the Bioactive Levels of the Hormone in Vivo
Endocrinology, July 1, 2008; 149(7): 3656 - 3667.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Attia, J. Eickhoff, G. Wilding, D. McNeel, J. Blank, H. Ahuja, A. Jumonville, M. Eastman, D. Shevrin, M. Glode, et al.
Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer
Clin. Cancer Res., April 15, 2008; 14(8): 2437 - 2443.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Kaeding, J. Belanger, P. Caron, M. Verreault, A. Belanger, and O. Barbier
Calcitrol (1{alpha},25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells
Mol. Cancer Ther., February 1, 2008; 7(2): 380 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Urushino, S. Nakabayashi, M. A. Arai, A. Kittaka, T. C. Chen, K. Yamamoto, K. Hayashi, S. Kato, M. Ohta, M. Kamakura, et al.
Kinetic Studies of 25-Hydroxy-19-nor-vitamin D3 and 1{alpha},25-Dihydroxy-19-nor-vitamin D3 Hydroxylation by CYP27B1 and CYP24A1
Drug Metab. Dispos., September 1, 2007; 35(9): 1482 - 1488.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Xu, F. Fang, D. K. St. Clair, S. Josson, P. Sompol, I. Spasojevic, and W. H. St. Clair
Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1{alpha},25-dihydroxyvitamin D3 in prostate cancer cells
Mol. Cancer Ther., July 1, 2007; 6(7): 2048 - 2056.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. M. Beer, C. W. Ryan, P. M. Venner, D. P. Petrylak, G. S. Chatta, J. D. Ruether, C. H. Redfern, L. Fehrenbacher, M. N. Saleh, D. M. Waterhouse, et al.
Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators
J. Clin. Oncol., February 20, 2007; 25(6): 669 - 674.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. M. Beer, M. Garzotto, B. Park, M. Mori, A. Myrthue, N. Janeba, D. Sauer, and K. Eilers
Effect of Calcitriol on Prostate-Specific Antigen In vitro and in Humans.
Clin. Cancer Res., May 1, 2006; 12(9): 2812 - 2816.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Ikezoe, S. Gery, D. Yin, J. O'Kelly, L. Binderup, N. Lemp, H. Taguchi, and H. P. Koeffler
CCAAT/Enhancer-Binding Protein {delta}: A Molecular Target of 1,25-Dihydroxyvitamin D3 in Androgen-Responsive Prostate Cancer LNCaP Cells
Cancer Res., June 1, 2005; 65(11): 4762 - 4768.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. M. Beer, A. Myrthue, M. Garzotto, M. F. O'Hara, R. Chin, B. A. Lowe, M. A. Montalto, C. L. Corless, and W. D. Henner
Randomized Study of High-Dose Pulse Calcitriol or Placebo prior to Radical Prostatectomy
Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2225 - 2232.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Swamy, T. C. Chen, S. Peleg, P. Dhawan, S. Christakos, L. V. Stewart, N. L. Weigel, R. G. Mehta, M. F. Holick, and R. Ray
Inhibition of Proliferation and Induction of Apoptosis by 25-Hydroxyvitamin D3-3{beta}-(2)-Bromoacetate, a Nontoxic and Vitamin D Receptor-Alkylating Analog of 25-Hydroxyvitamin D3 in Prostate Cancer Cells
Clin. Cancer Res., December 1, 2004; 10(23): 8018 - 8027.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
L. V. Stewart and N. L. Weigel
Vitamin D and Prostate Cancer
Experimental Biology and Medicine, April 1, 2004; 229(4): 277 - 284.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. M. Beer and A. Myrthue
Calcitriol in cancer treatment: From the lab to the clinic
Mol. Cancer Ther., March 1, 2004; 3(3): 373 - 381.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
G. Liu, G. Wilding, M. J. Staab, D. Horvath, K. Miller, A. Dresen, D. Alberti, R. Arzoomanian, R. Chappell, and H. H. Bailey
Phase II Study of 1{alpha}-Hydroxyvitamin D2 in the Treatment of Advanced Androgen-independent Prostate Cancer
Clin. Cancer Res., September 15, 2003; 9(11): 4077 - 4083.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
D. M. Peehl, A. V. Krishnan, and D. Feldman
Pathways Mediating the Growth-Inhibitory Actions of Vitamin D in Prostate Cancer
J. Nutr., July 1, 2003; 133(7): 2461S - 2469.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. Kumagai, J. O'Kelly, J. W. Said, and H. P. Koeffler
Vitamin D2 Analog 19-nor-1,25-Dihydroxyvitamin D2: Antitumor Activity Against Leukemia, Myeloma, and Colon Cancer Cells
J Natl Cancer Inst, June 18, 2003; 95(12): 896 - 905.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. C. Polek, L. V. Stewart, E. J. Ryu, M. B. Cohen, E. A. Allegretto, and N. L. Weigel
p53 Is Required for 1,25-Dihydroxyvitamin D3-Induced G0 Arrest But Is Not Required for G1 Accumulation or Apoptosis of LNCaP Prostate Cancer Cells
Endocrinology, January 1, 2003; 144(1): 50 - 60.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. M. Beer, K. M. Eilers, M. Garzotto, M. J. Egorin, B. A. Lowe, and W. D. Henner
Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer
J. Clin. Oncol., January 1, 2003; 21(1): 123 - 128.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Liu, K. Oettel, G. Ripple, M. J. Staab, D. Horvath, D. Alberti, R. Arzoomanian, R. Marnocha, R. Bruskewitz, R. Mazess, et al.
Phase I Trial of 1{alpha}-Hydroxyvitamin D2 in Patients with Hormone Refractory Prostate Cancer
Clin. Cancer Res., September 1, 2002; 8(9): 2820 - 2827.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. M. Perez-Stable, G. G. Schwartz, A. Farinas, M. Finegold, L. Binderup, G. A. Howard, and B. A. Roos
The G{gamma}/T-15 Transgenic Mouse Model of Androgen-independent Prostate Cancer: Target Cells of Carcinogenesis and the Effect of the Vitamin D Analogue EB 1089
Cancer Epidemiol. Biomarkers Prev., June 1, 2002; 11(6): 555 - 563.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
J. M Chan, M. J Stampfer, J. Ma, P. H Gann, J M. Gaziano, and E. L Giovannucci
Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study
Am. J. Clinical Nutrition, October 1, 2001; 74(4): 549 - 554.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Carducci, J. Gilbert, M. K. Bowling, D. Noe, M. A. Eisenberger, V. Sinibaldi, Y. Zabelina, T.-l. Chen, L. B. Grochow, and R. C. Donehower
A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule
Clin. Cancer Res., October 1, 2001; 7(10): 3047 - 3055.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J.-Y. Hsu, D. Feldman, J. E. McNeal, and D. M. Peehl
Reduced 1{{alpha}}-hydroxylase Activity in Human Prostate Cancer Cells Correlates with Decreased Susceptibility to 25-Hydroxyvitamin D3-induced Growth Inhibition
Cancer Res., April 1, 2001; 61(7): 2852 - 2856.
[Abstract] [Full Text]

Home page
 Pharmacol. Rev.Home page
S. C. Dixon, K. B. Knopf, and W. D. Figg
The Control of Prostate-Specific Antigen Expression and Gene Regulation by Pharmacological Agents
Pharmacol. Rev., March 1, 2001; 53(1): 73 - 92.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
K. El Abdaimi, V. Papavasiliou, D. Goltzman, and R. Kremer
Expression and regulation of parathyroid hormone-related peptide in normal and malignant melanocytes
Am J Physiol Cell Physiol, October 1, 2000; 279(4): C1230 - C1238.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. M. Barreto, G. G. Schwartz, R. Woodruff, and S. D. Cramer
25-Hydroxyvitamin D3, the Prohormone of 1,25-Dihydroxyvitamin D3, Inhibits the Proliferation of Primary Prostatic Epithelial Cells
Cancer Epidemiol. Biomarkers Prev., March 1, 2000; 9(3): 265 - 270.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
T. C. Chen, G. G. Schwartz, K. L. Burnstein, B. L. Lokeshwar, and M. F. Holick
The in Vitro Evaluation of 25-Hydroxyvitamin D3 and 19-nor-1{{alpha}},25-Dihydroxyvitamin D2 as Therapeutic Agents for Prostate Cancer
Clin. Cancer Res., March 1, 2000; 6(3): 901 - 908.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
S. E. Blutt, T. C. Polek, L. V. Stewart, M. W. Kattan, and N. L. Weigel
A Calcitriol Analogue, EB1089, Inhibits the Growth of LNCaP Tumors in Nude Mice
Cancer Res., February 1, 2000; 60(4): 779 - 782.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
S. E. Blutt, T. J. McDonnell, T. C. Polek, and N. L. Weigel
Calcitriol-Induced Apoptosis in LNCaP Cells Is Blocked By Overexpression of Bcl-2
Endocrinology, January 1, 2000; 141(1): 10 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Habuchi, T. Suzuki, R. Sasaki, L. Wang, K. Sato, S. Satoh, T. Akao, N. Tsuchiya, N. Shimoda, Y. Wada, et al.
Association of Vitamin D Receptor Gene Polymorphism with Prostate Cancer and Benign Prostatic Hyperplasia in a Japanese Population
Cancer Res., January 1, 2000; 60(2): 305 - 308.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
J.-i. Hisatake, T. Kubota, Y. Hisatake, M. Uskokovic, S. Tomoyasu, and H. P. Koeffler
5,6-trans-16-ene-Vitamin D3: A New Class of Potent Inhibitors of Proliferation of Prostate, Breast, and Myeloid Leukemic Cells
Cancer Res., August 1, 1999; 59(16): 4023 - 4029.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. H. Ly, X.-Y. Zhao, L. Holloway, and D. Feldman
Liarozole Acts Synergistically with 1{alpha},25-Dihydroxyvitamin D3 to Inhibit Growth of DU 145 Human Prostate Cancer Cells by Blocking 24-Hydroxylase Activity
Endocrinology, May 1, 1999; 140(5): 2071 - 2076.
[Abstract] [Full Text]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
B. L. Lokeshwar, G. G. Schwartz, M. G. Selzer, K. L. Burnstein, S.-H. Zhuang, N. L. Block, and L. Binderup
Inhibition of Prostate Cancer Metastasis in Vivo: A Comparison of 1,25-Dihydroxyvitamin D (Calcitriol) and EB1089
Cancer Epidemiol. Biomarkers Prev., March 1, 1999; 8(3): 241 - 248.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
X.-Y. Zhao, L. H. Ly, D. M. Peehl, and D. Feldman
Induction of Androgen Receptor by 1{alpha},25-Dihydroxyvitamin D3 and 9-cis Retinoic Acid in LNCaP Human Prostate Cancer Cells
Endocrinology, March 1, 1999; 140(3): 1205 - 1212.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
K. A. Moffatt, W. U. Johannes, and G. J. Miller
1{{alpha}},25-Dihydroxyvitamin D3 and Platinum Drugs Act Synergistically to Inhibit the Growth of Prostate Cancer Cell Lines
Clin. Cancer Res., March 1, 1999; 5(3): 695 - 703.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
C. Agarwal, A. Lambert, R. A.S. Chandraratna, E. A. Rorke, and R. L. Eckert
Vitamin D Regulates Human Ectocervical Epithelial Cell Proliferation and Insulin-Like Growth Factor-Binding Protein-3 Level
Biol Reprod, March 1, 1999; 60(3): 567 - 572.
[Abstract] [Full Text]

Home page
 BloodHome page
H. Asou, M. Koike, E. Elstner, M. Cambell, J. Le, M. R. Uskokovic, N. Kamada, and H. P. Koeffler
19-nor Vitamin-D Analogs: A New Class of Potent Inhibitors of Proliferation and Inducers of Differentiation of Human Myeloid Leukemia Cell Lines
Blood, October 1, 1998; 92(7): 2441 - 2449.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Wu, R. S. Fan, W. Li, V. Srinivas, and M. G. Brattain
Regulation of Transforming Growth Factor-beta Type II Receptor Expression in Human Breast Cancer MCF-7 Cells by Vitamin D3 and Its Analogues
J. Biol. Chem., March 27, 1998; 273(13): 7749 - 7756.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
X.-Y. Zhao, L. H. Ly, D. M. Peehl, and D. Feldman
1{alpha},25-Dihydroxyvitamin D3 Actions in LNCaP Human Prostate Cancer Cells Are Androgen-Dependent
Endocrinology, August 1, 1997; 138(8): 3290 - 3298.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. E. Blutt, E. A. Allegretto, J. W. Pike, and N. L. Weigel
1,25-Dihydroxyvitamin D3 and 9-cis-Retinoic Acid Act Synergistically to Inhibit the Growth of LNCaP Prostate Cells and Cause Accumulation of Cells in G1
Endocrinology, April 1, 1997; 138(4): 1491 - 1497.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
X.-Y. Zhao, T. R. Eccleshall, A. V. Krishnan, C. Gross, and D. Feldman
Analysis of Vitamin D Analog-Induced Heterodimerization of Vitamin D Receptor with Retinoid X Receptor Using the Yeast Two-Hybrid System
Mol. Endocrinol., March 1, 1997; 11(3): 366 - 378.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
I. M. Musiol and D. Feldman
1,25-Dihydroxyvitamin D3 Induction of Nerve Growth Factor in L929 Mouse Fibroblasts: Effect of Vitamin D Receptor Regulation and Potency of Vitamin D3 Analogs
Endocrinology, January 1, 1997; 138(1): 12 - 18.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society